GCGR Human
E. coli
GL-R, GLR, Glucagon Receptor.
Greater than 95.0% as determined by SDS-PAGE.
THE BioTek's products are furnished for LABORATORY RESEARCH USE ONLY. They may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Description
GCGR Human Recombinant produced in E. coli is a single, non-glycosylated polypeptide chain (a.a 29-142) containing 125 amino acids including an 8 a.a C-terminal His tag. The total molecular mass is 19.9kDa (calculated).
Product Specs
GL-R, GLR, Glucagon Receptor.
E. coli
MQVMDFLFEK WKLYGDQCHH NLSLLPPPTE LVCNRTFDKY SCWPDTPANT TANISCPWYL PWHHKVQHRF VFKRCGPDGQ WVRGPRGQPW RDASQCQMDG EEIEVQKEVA KMYSSFQLEH HHHHH.
Product Science Overview
The glucagon receptor is a 62 kDa protein that belongs to the class B family of GPCRs. It is primarily expressed in the liver and kidneys, with lesser amounts found in the heart, adipose tissue, spleen, thymus, adrenal glands, pancreas, cerebral cortex, and gastrointestinal tract . Upon binding with glucagon, the receptor activates adenylate cyclase, which increases intracellular cyclic AMP (cAMP) and activates protein kinase A. This cascade ultimately leads to the breakdown of glycogen and the release of glucose into the bloodstream .
When glucagon binds to its receptor, it activates Gs and Gq proteins. The activation of Gs proteins stimulates adenylate cyclase, leading to an increase in cAMP levels. This, in turn, activates protein kinase A, which phosphorylates glycogen phosphorylase kinase. This kinase then phosphorylates glycogen phosphorylase, leading to the breakdown of glycogen into glucose . Additionally, the activation of Gq proteins leads to the activation of phospholipase C, which increases the production of inositol 1,4,5-triphosphate and releases intracellular calcium .
Recombinant glucagon receptors are produced using recombinant DNA technology, which allows for the expression of the human glucagon receptor in various host cells. This technology is crucial for studying the receptor’s function and for developing therapeutic agents that target the receptor. Recombinant glucagon receptors are used in various research applications, including drug screening and the study of signal transduction pathways .
The glucagon receptor is a target for the treatment of various metabolic disorders, including diabetes mellitus. By understanding the receptor’s structure and function, researchers can develop drugs that modulate its activity to regulate blood glucose levels. For example, glucagon receptor antagonists are being investigated as potential treatments for hyperglycemia in diabetic patients .
